期刊文献+

白介素6基因启动子-572C/G多态性与非酒精性脂肪肝炎的关系 被引量:3

C/G homozygotes of interleukin-6 single nucleotide polymorphism at-572 are associated with nonalcoholic steatohepatitis
下载PDF
导出
摘要 目的:探讨白介素6(IL-6)基因启动子-572C/G多态性与非酒精性脂肪肝炎(NASH)相关性.方法:应用聚合酶联反应-限制性片段长度多态性(PCR-RFLP)方法,分别检测NASH患者78例和正常者104例IL-6基因启动子-572C/G多态性的变异.采用ELISA法检测NASH患者组IL-6血清含量.结果:IL-6基因启动子-572位点的C等位基因频率高于健康对照组,两组基因分布频率有显著统计学差异(0.564 vs 0.404,P<0.05):NASH患者组中CC基因型携带者IL-6血清含量显著高于其他基因型携带者(6.54±4.21 vs 4.68±2.88,P<0.05),但HOMA-IR及BMI与其他两组基因型相比较并无显著统计学差异.结论:IL-6基因启动子-572位点的C等位基因与NASH发病具有一定程度相关性. AIM:To investigate the relationship between the C/G genotypes of interleukin-6(IL-6)single nucleotide polymorphism(SNP)at 572 and the development of nonalcoholic steatohepatitis (NASH). METHODS:Polymerase chain reaction-restriction fragment length polymorphism(PCR-RFLP) was used to determine a common polymorphism of the human IL-6 gene-572C/G in 104 controls and NASH 78 patients.Enzyme linked immunosorbent assay(ELISA)was used to determine the concentration of serum IL-6 in 78 patients with NASH. RESULTS:Homozygotes for-572C of IL-6 gene were more frequent in NASH patients than in controls(0.564 vs 0.404,P〈0.05).Level of IL-6 was significantly higher in NASH patients with IL-6-572C/C genotype than that in NASH patients with other genotypes(6.54±4.21 vs 4.68±2.88,P〈0.05).The significant difference in HOMA-IR was not seen in three genotypes. CONCLUSION:The C/G homozygotes of IL-6 single nucleotide polymorphism at-572 have something to do with the pathogenesis of NASH.
出处 《世界华人消化杂志》 CAS 北大核心 2008年第6期635-639,共5页 World Chinese Journal of Digestology
关键词 白细胞介素6 单核苷酸多态性 胰岛素抵抗 非酒精性脂肪肝炎 Interleukin-6 Single nucleotide polymorphism Insulin resistance Nonalcoholic steatohepatitis
  • 相关文献

参考文献22

  • 1Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24:3-20.
  • 2Ratziu V, Tahiri M, Bonyhay L. Nonalcoholic steatohepatitis. Ann Endocrinol (Paris) 2005; 66: 1S71-1S80.
  • 3Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40:1286-1292.
  • 4橋本悦子,谷仁烨.非酒精性脂肪性肝炎的诊断标准[J].日本医学介绍,2007,28(4):146-148. 被引量:5
  • 5范建高.亚太地区非酒精性脂肪性肝病诊断与治疗共识简介[J].中华肝脏病杂志,2007,15(7):552-553. 被引量:51
  • 6Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114:842-845.
  • 7Casano-Sancho P, Lopez-Bermejo A, FernandezReal JM, Monros E, Valls C, Rodriguez-Gonzalez FX, Ricart W, Ibanez L. The tumour necrosis factor (TNF)-alpha-308GA promoter polymorphism is related to prenatal growth and postnatal insulin resistance. Clin Endocrinol (Oxf) 2006; 64:129-135.
  • 8Yang X, Jansson PA, Pellme F, Laakso M, Smith U. Effect of the interleukin-6 (-174) g/c promoter polymorphism on adiponectin and insulin sensitivity. Obes Res 2005; 13:813-817.
  • 9Qi L, van Dam RM, Meigs JB, Manson JE, Hunter D, Hu FB. Genetic variation in IL6 gene and type 2 diabetes: tagging-SNP haplotype analysis in largescale case-control study and meta-analysis. Hum Mol Genet 2006; 15:1914-1920.
  • 10Fernandez-Real JM, Broch M, Vendrell J, Richart C, Ricart W. Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 2000; 85:1334-1339.

二级参考文献23

  • 1杨冀衡,陆泽元,许香广,林怿昊,罗国辉.代谢综合征患者胰岛素抵抗的影响因素[J].中国动脉硬化杂志,2004,12(4):452-454. 被引量:5
  • 2[1]Ross R.Atheroselerosis-an inflammataory disease.N Engl J Med,1999,340:115-126.
  • 3[2]Daley GQ,Cargill M.The heart SNPs a beat:Polymorphisms in candidate genes for cardiovascular disease.Trends Cardiovasc Med,2001,1:60-66.
  • 4[4]Fishman D,Faulds G,Jeffery R,et al.The effect of novel polymorphisms in the interleukin-6 (IL-6)gene on IL-6 transefiption and plasma 1L-6 levels,and all association with systemiconset juvenile chronic arthritis.J Clin Invest,1998,102:1369-1376.
  • 5[5]Brull DJ,Momtgomery HE,Sandem J,et al.Interleukin-6 gene174g>c and-572g>c promoter poly-morphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery.Arterioseler.Thromb.Vasc.Biol,2001,21:1458-1463.
  • 6[6]Tian ZG,Li KS.Interleukine-6 and dysimmunity diseases.Shanghai Mien I hsueh Tsa Chih(in Chinese),1990,10:189-191.
  • 7[7]Ridker PM,Rifai N,Stampfer MJ,et al.Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.Circulation,2000,101:1767-1772.
  • 8[9]Tsucyasu K,Takashi T.Interleukin-6 and cardiovascular diseases.J pn Heart J,2004,45:183.
  • 9[10]Daley GQ,Cargill M.The Heart SNPs a Beat:polymorphisms in candidate genes for cardiovascular disease.Trends Cardiovasc Med,2001,1:60-66.
  • 10Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia, 1997, 40: 1 286-292.

共引文献66

同被引文献36

引证文献3

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部